1. Case Report of Increased Exposure to Antiretrovirals following Sleeve Gastrectomy
- Author
-
Roni Gibori, Arik Dahan, Carmil Azran, Ehud Horwitz, Hila Elinav, Sarah Israel, Daniel Porat, and Ram Elazary
- Subjects
Adult ,Male ,medicine.medical_specialty ,Sleeve gastrectomy ,Pyridones ,medicine.medical_treatment ,Human immunodeficiency virus (HIV) ,Bariatric Surgery ,HIV Infections ,Morbidly obese ,medicine.disease_cause ,030226 pharmacology & pharmacy ,Antiviral Agents ,Piperazines ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Abacavir ,Gastrectomy ,Internal medicine ,0502 economics and business ,Oxazines ,Medicine ,Humans ,Pharmacology (medical) ,Pharmacology ,medicine.diagnostic_test ,business.industry ,05 social sciences ,Lamivudine ,virus diseases ,Dideoxynucleosides ,Obesity, Morbid ,Infectious Diseases ,chemistry ,Anti-Retroviral Agents ,Therapeutic drug monitoring ,Dolutegravir ,Hiv patients ,050211 marketing ,Drug Monitoring ,business ,Heterocyclic Compounds, 3-Ring ,medicine.drug - Abstract
Bariatric surgery is increasingly performed in morbidly obese HIV patients. Limited data exist regarding antiretroviral drug exposure after bariatric surgery. We report a case of a morbidly obese HIV patient who underwent sleeve gastrectomy. Abacavir, lamivudine, and dolutegravir therapeutic drug monitoring was performed at several time points pre- and postsurgery. Significantly increased levels were measured, particularly for abacavir, whose levels increased ∼12-fold. Several mechanistic explanations for these findings are discussed.
- Published
- 2020